This article is more than 5 years old. Information may no longer be current.

INS365 effective in dry eyes, moves to Phase 3

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. — INS365 (Inspire) has proven efficacious in patients with dry eye and has been recommended to be moved onto Phase 3 trials.

In a scientific symposium held at the Association for Research in Vision and Ophthalmology (ARVO) meeting here, Gary Foulks, MD, said that positive trends were observed for improvement in both objective and subjective endpoints. Among those criteria that showed positive results were: staining, Schirmer tests, itching and burning.

For more, click here.